Ripening agent having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity

By using a combination of ALK5 and CDK8/19 inhibitors in the pancreatic precursor cell population, the use of ALK5iII was avoided, and the problems of its mutagenicity and low differentiation efficiency were solved, and efficient induction of insulin-positive cell population was achieved.

CN119072542APending Publication Date: 2024-12-03ORIZURU THERAPEUTICS INC
View PDF 27 Cites 0 Cited by

Patent Information

Application Number
CN202380035825.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-25
Filing Date
2023-04-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The use of the ALK5 inhibitor ALK5iII in the prior art may lead to irreversible changes or mutations in biological genetic information during the differentiation induction of insulin-positive cell populations, and its substitutes lead to a reduced differentiation efficiency and cannot effectively create an insulin-positive cell population.

Method used

The use of ALK5iII is avoided by using factors with ALK5 inhibitory activity and CDK8/19 inhibitory activity in pancreatic precursor cell populations or cell populations at subsequent differentiation stages, and induction of insulin with a combination of ALK5 inhibitors and CDK8/19 inhibitors. Differentiation of positive cells.

Benefits of technology

Differentiation induction of insulin-positive cell populations with low mutagenicity or non-mutagenicity is achieved, and the efficiency is no less than that of the ALK5iII method, providing a safe and reliable new method to create insulin-positive cell populations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005097828660000071
    Figure BDA0005097828660000071
  • Figure BDA0005097828660000081
    Figure BDA0005097828660000081
  • Figure BDA0005097828660000101
    Figure BDA0005097828660000101
Patent Text Reader

Abstract

The purpose of the present invention is to provide a novel method for inducing a population of insulin-positive cells from the differentiation of pluripotent stem cells, and to provide a method for producing a population of insulin-positive cells, the method comprises culturing and differentiating a pancreatic precursor cell population or a cell population in a differentiation stage thereafter in a culture medium that does not substantially contain 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1, 5-naphthyridine and contains factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing an insulin-positive cell population from pluripotent stem cells. More specifically, the present invention relates to a method for producing an insulin-positive cell population, characterized in that a pancreatic precursor cell population obtained by differentiation induction of pluripotent stem cells or a cell population in a subsequent differentiation stage is interacted with a factor having inhibitory activity against cyclin-dependent kinase 8 and / or cyclin-dependent kinase 19 (hereinafter, sometimes described as "CDK8 / 19") and inhibitory activity against ALK5. Background Art

[0002] Currently, research is being conducted on inducing insulin-positive cells or pancreatic β cells from pluripotent stem cells such as iPS cells or ES cells, and applying them to the treatment of diabetes.

[0003] So far, various methods for inducing differentiation of pluripotent stem cells into insulin-positive cell groups have been developed and reported (non-patent literature 1). However, in the insulin-positive cell group obtained by differentiation induction, in addition to the insulin-positive cells as the target (particularly insulin-positive and NKX6.1-positive cells, etc.), residual relatively undifferentiated cells may also be included, or various cells such as malignant transformed cells. When the insulin-positive cell group is intended to be applied to diabetes treatment, from the viewpoint of safety, it is extremely important to strictly control the types of cells contained in the cell group. Therefore, there is an urgent need for a differentiation induction method of a new insulin-positive cell group that can not include more non-target cells. Prior art literature Non-patent literature

[0004] Non-patent literature 1: Stem Cell Research (2015) 14, 185-197 Summary of the invention Problems to be solved by the present invention

[0005] The present inventors have discovered that the ALK5 inhibitor 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine (sometimes also referred to as "transforming growth factor-βtype I receptor kinase", "activin receptor-like kinase 5inhibitor II", "ALK5iII", "E 616452", "RepSox" or "SJN 2511". Hereinafter, in this specification, it may be simply referred to as ALK5iII) used in the process of inducing insulin-positive cell populations by differentiation from pluripotent stem cells in the past, more specifically, in the process of inducing endocrine precursor cells and / or cells in a subsequent differentiation stage by differentiation from pancreatic precursor cells, may cause irreversible changes or mutations in the genetic information of organisms (i.e., it is mutagenic). Therefore, it is best to avoid using ALK5iII during differentiation induction. However, it was found that if other ALK5 inhibitors were used instead of ALK5iII, the efficiency of differentiation induction into the target cell population would be reduced, and the insulin-positive cell population could not be produced as well as ALK5iII.

[0006] Therefore, the purpose of the present invention is to find a new differentiation-inducing factor to replace ALK5iII, which can effectively induce the above-mentioned differentiation and has low or no mutagenicity, and to provide a new method for inducing insulin-positive cell populations by differentiating pluripotent stem cells using this new differentiation-inducing factor. Technical solutions to the problem

[0007] As a result of the inventors' intensive research to solve the above-mentioned problems, they found that in the process of inducing insulin-positive cell populations from pluripotent stem cells, by allowing the pancreatic precursor cell population or the cell population in the subsequent differentiation stage to act with factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity rather than with ALK5iII, insulin-positive cells, especially insulin-positive and NKX6.1-positive cells, can be effectively differentiated and induced, thereby achieving differentiation induction that is not inferior to the previous method using ALK5iII.

[0008] The present invention is based on these new findings and includes the following inventions. [1] A method for producing an insulin-positive cell population, The method comprises: culturing and differentiating a pancreatic precursor cell population or a cell population at a subsequent differentiation stage in a culture medium containing factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, The culture medium is substantially free of 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine. [2] The method according to [1], wherein the factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity comprises an ALK5 inhibitor and a CDK8 / 19 inhibitor. [3] The method according to [2], wherein the CDK8 / 19 inhibitor is selected from diethyl (E)-(4-(3-(5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)acrylamide)benzyl)phosphonate, 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile, 4-(4-( One or more compounds or their salts thereof are selected from the group consisting of (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-pyrazol-3-yl)benzene-1,3-diol, 3-(2-(imidazo[1,2-b]pyridazin-6-ylthio)ethyl)-4-(naphthalen-1-ylsulfonyl)-3,4-dihydroquinoxalin-2(1H)-one, and (E)-3-(4-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinylmethyl)phenyl)acrylamide. [4] The method according to [2], wherein the ALK5 inhibitor is one or more compounds selected from the group consisting of 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, and 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline, or a salt thereof. [5] The method according to [2], wherein the CDK8 / 19 inhibitor is 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile or 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide or a salt thereof, and the ALK5 inhibitor is 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide or a salt thereof. [6] The method according to [1], wherein the pancreatic precursor cell population or the cell population at a subsequent differentiation stage is produced by differentiating induced pluripotent stem cells. [7] A differentiation medium for a pancreatic precursor cell population or a cell population at a subsequent differentiation stage, the medium comprising factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity and being substantially free of 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine. [8] The culture medium according to [7], wherein the factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity comprises an ALK5 inhibitor and a CDK8 / 19 inhibitor. [9] The culture medium according to [8], wherein the CDK8 / 19 inhibitor is selected from diethyl (E)-(4-(3-(5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)acrylamide)benzyl)phosphonate, 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile, 4-(4- One or more compounds or their salts thereof are selected from the group consisting of (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-pyrazol-3-yl)benzene-1,3-diol, 3-(2-(imidazo[1,2-b]pyridazin-6-ylthio)ethyl)-4-(naphthalen-1-ylsulfonyl)-3,4-dihydroquinoxalin-2(1H)-one, and (E)-3-(4-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinylmethyl)phenyl)acrylamide.

[10] The culture medium according to [8], wherein the ALK5 inhibitor is one or more compounds selected from the group consisting of 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, and 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline, or a salt thereof.

[11] The culture medium according to [8], wherein the CDK8 / 19 inhibitor is 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile or 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide or a salt thereof, and the ALK5 inhibitor is 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide or a salt thereof.

[12] The culture medium according to [7], wherein the pancreatic precursor cell population or the cell population in a subsequent differentiation stage is produced by differentiating induced pluripotent stem cells. This specification includes the contents described in the specification of Japanese Patent Application No. 2022-071507 filed on April 25, 2022, which is the basis of priority of this application. All publications, patents and patent applications cited in this specification are directly incorporated into this specification as reference. Effects of the Invention

[0009] According to the present invention, there can be provided a new differentiation-inducing factor that can be used instead of ALK5iII, has low or no mutagenicity, and can effectively induce differentiation from pluripotent stem cells to insulin-positive cells, as well as a novel method for inducing differentiation of insulin-positive cell populations from pluripotent stem cells using the new differentiation-inducing factor. BRIEF DESCRIPTION OF THE DRAWINGS

[0010]

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

[0011] 1. Terminology The following is a description of the terms used in this specification.

[0012] In this specification, "about" or "approximately" means a value fluctuating within plus or minus 25%, 20%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or 1% relative to a reference value, respectively. Preferably, the term "about" or "approximately" means a range of plus or minus 15%, 10%, 5% or 1% relative to a reference value, respectively.

[0013] In this specification, "comprise(s) or comprising~" means including / containing the elements following the sentence, but is not limited thereto. Therefore, although it implies including / containing the elements following the sentence, it does not imply excluding any other elements.

[0014] In this specification, "consist(s) of or consisting of" means including and limited to all the elements following the sentence. Therefore, the sentence "consist(s) of" means that the listed elements are essential or necessary, and there are substantially no other elements.

[0015] In this specification, "not using feeder cells" means that feeder cells are substantially not contained, and a medium pretreated by culturing feeder cells is not used, etc. Therefore, the medium does not contain substances such as growth factors and cytokines secreted by feeder cells.

[0016] In addition, "feeder cells" or "feeders" refer to cells that are co-cultured with other types of cells and are provided with an environment that can support the cells and make them grow. Feeder cells can be of the same source as the cells they support, or they can be of different sources. For example, as feeders for human cells, human skin fibroblasts or human embryonic stem cells can be used, and primary cultures of mouse embryonic fibroblasts and immortalized mouse embryonic fibroblasts can also be used. Feeder cells can be inactivated by radiation irradiation or mitomycin C treatment.

[0017] In this specification, "adhesion" refers to the attachment of cells to a container, for example, cells adhere to a sterile plastic (or coated plastic) cell culture dish or flask in the presence of an appropriate culture medium. There are cells that cannot be maintained or grown in culture without adhering to the cell culture container. Non-adherent cells can still be maintained and proliferated in culture without adhering to the container.

[0018] In this specification, "culture" means maintaining cells in an in vitro environment and causing them to grow and / or differentiate. "Cultivating" means causing cells to continue, proliferate and / or differentiate in a tissue or in vitro, such as in a cell culture dish or flask. Cultivation includes two-dimensional culture (planar culture) and three-dimensional culture (suspension culture).

[0019] In this specification, "enrichment" and "enrichment" refer to increasing the amount of a specific constituent in a composition such as a composition of cells; "enriched", when used to describe a composition of cells such as a cell group, refers to a cell group in which the amount of a specific constituent is increased compared to the proportion of the constituent in the cell group before enrichment. For example, a composition such as a cell group related to a target cell type can be enriched, so that the proportion of the target cell type is increased compared to the proportion of target cells present in the cell group before enrichment. Cell groups related to target cell types can also be enriched by cell selection and screening methods known in the art. Cell groups can also be enriched by specific screening or selection processes described in this specification. In a specific embodiment of the present invention, a cell group related to a target cell group is enriched by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99%.

[0020] In this specification, "deplete" and "depletion" refer to reducing the amount of a specific constituent in a composition such as a composition of cells; "depleted", when used to describe a composition of cells such as a cell group, refers to a cell group in which the amount of a specific constituent is reduced compared to the proportion of the specific constituent in the cell group before depletion. For example, a composition such as a cell group related to a target cell type can be depleted, so that the proportion of the target cell type is reduced compared to the proportion of target cells present in the cell group before depletion. The cell group related to the target cell type can also be depleted by cell selection and screening methods known in the art. The cell group can also be depleted by a specific screening or selection process described in this specification. In a specific embodiment of the present invention, the cell group related to the target cell group is reduced (depleted) by at least 50%, 80%, 85%, 90%, 95%, 97%, 98% or 99% by a method for depleting the target cell group.

[0021] In this specification, "purify" and "purification" refer to the removal of impurities in a composition such as a composition of cells, so that a specific constituent component becomes pure; "purified", when used to describe a composition of cells such as a cell group, refers to a cell group in which the amount of impurities is reduced compared to the proportion of the constituent component in the cell group before purification, and the purity of the specific constituent component is improved. For example, a composition such as a cell group related to a target cell type can be purified, so that the proportion of the target cell type is increased compared to the proportion of target cells present in the cell group before purification. The cell group related to the target cell type can also be purified by cell selection and screening methods known in the art. The cell group can also be purified by a specific screening or selection process described in this specification. In a specific embodiment of the present invention, the purity of the target cell group is made to be at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% by a method for purifying the target cell group, or it can be made to a degree where impurities (including mixed cells) cannot be detected.

[0022] In this specification, "marker" means a cell antigen or its gene that is specifically expressed by a specified cell type, such as a "marker protein" or "marker gene". Preferably, the marker is a cell surface marker, in which case, concentration, separation and / or detection of surviving cells can be performed. The marker can be a positive selection marker or a negative selection marker.

[0023] The detection of the marker protein can be performed by immunological analysis using antibodies specific for the marker protein, such as ELISA, immunostaining, and flow cytometry. The detection of the marker gene can be performed using nucleic acid amplification methods and / or nucleic acid detection methods known in the art, such as RT-PCR, microarrays, biochips, etc. In this specification, the marker protein is "positive" means that it is detected as positive by flow cytometry, and "negative" means that it is below the detection limit by flow cytometry. In addition, in this specification, the marker gene is "positive" means that it is detected by RT-PCR, and "negative" means that it is below the detection limit by RT-PCR.

[0024] In the present specification, "expression" is defined as the transcription and / or translation of a specific nucleotide sequence driven by a promoter in a cell.

[0025] In the present specification, "growth factor" refers to an endogenous protein that promotes differentiation and / or proliferation of specific cells. Examples of "growth factor" include epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), transferrin, various interleukins (e.g., IL-1 to IL-18), various colony stimulating factors (e.g., granulocyte / macrophage-colony stimulating factor (GM-CSF), various interferons (e.g., IFN-γ, etc.), and other cytokines effective for stem cells, such as stem cell factor (SCF) and erythropoietin (Epo).

[0026] In the present specification, "ROCK inhibitor" means a substance that inhibits Rho kinase (ROCK: Rho-associated, coiled-coil containing protein kinase), and may be a substance that inhibits either ROCK I or ROCK II. The ROCK inhibitor is not particularly limited as long as it has the above-mentioned function, and examples thereof include N-(4-pyridyl)-4β-[(R)-1-aminoethyl]cyclohexane-1α-carboxamide (sometimes referred to as Y-27632 in the present specification), Fasudil (HA1077), (2S)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]hexahydro-1H-1,4-diazepine (H-1152), 4β-[(1R)-1-aminoethyl]-N-(4-pyridyl)benzene-1α-carboxamide (Wf-536), N-(1H-pyrrolo[2,3-b] [4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide (GSK429286A). The ROCK inhibitor is not limited to the above, and antisense oligonucleotides or siRNA to ROCK mRNA, antibodies binding to ROCK, dominant negative ROCK mutants, etc. can also be used as ROCK inhibitors, which are commercially available or can be synthesized according to known methods.

[0027] In this specification, "GSK3β inhibitor" refers to a substance that has inhibitory activity on GSK3β (glycogen synthase kinase 3β). GSK3 (glycogen synthase kinase 3) is a type of serine / threonine protein kinase, which is involved in many signal transduction pathways such as glycogen production or apoptosis, maintenance of stem cells, etc. GSK3 has two isoforms, α and β. The "GSK3β inhibitor" used in the present invention is not particularly limited as long as it has GSK3β inhibitory activity, and can also be a substance that is combined with GSK3β inhibitory activity and has GSK3α inhibitory activity.

[0028] Examples of GSK3β inhibitors include CHIR98014 (2-[[2-[(5-nitro-6-aminopyridin-2-yl)amino]ethyl]amino]-4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidine), CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]-amino]ethyl]amino]nicotinonitrile), TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione), SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), and TWS-119 (3-[ 6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenol), Kenpaullone, 1-azakenpaullone, SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), SB415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione) and AR-AO144-18, CT99021, CT20026, BIO, BIO-acetone oxime, pyridocarbazole-cyclopentadienylruthenium complex, OTDZT, α-4-dibromoacetophenone, lithium, etc. GSK3β is not limited to the above, and antisense oligonucleotides or siRNA to GSK3β mRNA, antibodies binding to GSK3β, dominant negative GSK3β mutants, etc. can also be used as GSK3β inhibitors, which are commercially available or can be synthesized according to known methods.

[0029] The "serum replacement" in this specification includes, for example, KnockOut TMSerum Replacement (KSR: Thermo Fisher Scientific), StemSure (registered trademark) Serum Replacement (Wako), B-27 supplement, N2 supplement, albumin (e.g., lipid-rich albumin), insulin, transferrin, fatty acids, collagen precursors, trace elements (e.g., zinc, selenium (e.g., sodium selenite)), 2-mercaptoethanol, 3'-thioglycerol or a mixture thereof (e.g., ITS-G). As serum substitutes, B-27 supplement, KSR, StemSure (registered trademark) Serum Replacement, ITS-G are preferred. When the serum substitute is added to the culture medium, its concentration in the culture medium is 0.01%-10% by weight, preferably 0.1%-2% by weight. In the present invention, it is preferred to use a "serum substitute" instead of serum.

[0030] 2. Method for producing insulin-positive cell population The present invention provides a method for producing an insulin-positive cell population, the method comprising: culturing a pancreatic precursor cell population or a cell population in a subsequent differentiation stage in a culture medium having factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity and substantially free of ALK5iII to differentiate the cell population.

[0031] In the present invention, the culture medium only needs to contain a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, and the factor may be a single (or single) inhibitor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, or the factor may be a combination of a factor having ALK5 inhibitory activity (ALK5 inhibitor) and a plurality of factors having CDK8 / 19 inhibitory activity (CDK8 / 19 inhibitor). Preferably, in the present invention, the culture medium contains a combination of an ALK5 inhibitor and a CDK8 / 19 inhibitor.

[0032] For the culture medium of the present invention, "substantially free of ALK5iII" means that ALK5iII is not contained in the culture medium in a manner capable of exerting any activity including ALK5 inhibitory activity, and does not necessarily mean that the culture medium does not contain any ALK5iII at all. Preferably, it means that ALK5iII is not contained at all in the culture medium of the present invention. In addition, "ALK5iII" in the present invention includes salt and solubilized forms of ALK5iII, as long as these forms are mutagenic.

[0033] In this specification, "factors having CDK8 / 19 inhibitory activity" or "CDK8 / 19 inhibitors" means all substances having CDK8 / 19 inhibitory activity. Compared with other proteins in the CDK family, CDK8 is not essential for cell proliferation, and the inhibition of CDK8 does not have much effect under normal conditions. CDK19 is similar to CDK8, and the inhibition of CDK8 is usually accompanied by the inhibition of CDK19.

[0034] The "CDK8 / 19 inhibitor" used in the present invention is not particularly limited as long as it has CDK8 / 19 inhibitory activity, and all factors that directly or indirectly inhibit the function of CDK8 / 19 can be used.

[0035] In the present invention, the “CDK8 / 19 inhibitor” may be a conventionally known inhibitor, and such a CDK8 / 19 inhibitor can be found in patent documents or non-patent documents. For example, among the compounds described in US2012 / 0071477, WO 2015 / 159937, WO 2015 / 159938, WO 2013 / 116786, WO 2014 / 0038958, WO 2014 / 134169, JP 2015 / 506376, US2015 / 0274726, US2016 / 0000787, WO 2016 / 009076, WO 2016 / 0016951, WO 2016 / 018511, WO 2016 / 100782 and WO 2016 / 182904, compounds having CDK8 / 19 inhibitory activity or salts thereof can be used as the "CDK8 / 19 inhibitor" in the present invention. In particular, among the above-mentioned compounds, compounds having selective inhibitory activity against CDK8 / 19 or salts thereof can be suitably used.

[0036] More specifically, the CDK8 / 19 inhibitors that can be used in the present invention are not particularly limited, and examples thereof include the following compounds or salts thereof. In addition, as long as these compounds have CDK8 / 19 inhibitory activity, they may have one or more substituents, or may have a partial structure (substituent, ring, etc.) that is changed.

[0037]

Table 1

[0038] In addition, the CDK8 / 19 inhibitors that can be used in the present invention are not particularly limited, and for example, the following compounds 7 to 13 or salts thereof can be used. Compounds 7 to 11 are preferably free compounds, and compounds 12 and 13 are preferably trifluoroacetate salts.

[0039]

Table 2

[0040] In addition, the CDK8 / 19 inhibitors that can be used in the present invention are not particularly limited, and for example, the following compounds or salts thereof can be used: Senexin A (Cas. No. 1780390-76-2), UNC10112785 (N-(4-isopropylphenyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-amine), SEL120-34A (Cas. No. 1609452-30-3), MSC2530818 (Cas. No. 1883423-59-3), Cortistatin A (Cas. No. 882976-95-6), CDK8 / 19-IN-1 (Cas. No. 1818427-07-4), CDK8-IN-I (4-(4-methylnaphthalen-1-yl)-2-((3-morpholinophenyl)sulfonamido)benzoic acid), CDK8-IN-II (Cas. No. 1613638-82-6), CDK8-IN-3 (Cas. No. 1884500-15-5), CDK8-IN-III (Cas. No. 1814 891-79-6), CDK8-IN-4 (Cas. No. 1613638-82-6), CDK8-IN-IV ((Z)-16-chloro-11,21,25,61-tetramethyl-11H,21H,61H-10-oxo-4,8-dithia-1(7,3)-indole-2(4,3),6(3,5)-dipyrazole-9(3,1)-naphthalene heterocyclic tridecanol-12-carboxylic acid), CDK8 / 19-IN-4k (Cas. No. 1818410-84-2), C DK8 / 19-IN-18 (Cas. No. 1879980-97-8), CDK8 / 19-IN-32 (7-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide), BRD6989 (Cas. No. 642008-81-9), CCT251921 (Cas. No. 1607837-31-9), CCT251545 (Cas. No. 1661839-45-7), Wogonin (Cas. No. .632-85-9), JH-XVI-178(Cas.No.2648453-53-4), LY2857785(Cas.No.1619903-54-6), AS2863619(Cas.No.224 1300-51-4), 3MB-PP1 (Cas. No. 956025-83-5), CDK8 / 19i (Cas. No. 923596-52-5), H-8 (Hydrochloride) (Cas. No.294646-77-8), JH-VIII-49 ((3S,8S,10R,13S,14S,17S)-17-(isoquinolin-7-yl)-N,N,10,13-tetramethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3-amine), JH-XI-10-02 (Cas.No.2209085-22-1), SNX2-1-108 (Cas.No.1366002-73-4), W-34 (1-(3,4-dichloro-phenyl)-3-{1-[5-(4-chloro-benzyl)-[1,2,4]thiadiazol-3-yl]-piperidin-4-ylmethyl}-urea). .

[0041] Preferably, the CDK8 / 19 inhibitor that can be used in the present invention is 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide (also known as "BI-1347", or "1H-pyrazole-1-acetamide, 4-[4-(4-isoquinolinyl)phenyl]-N,N-dimethyl"), 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile (also known as "Senexin B" or "SNX-2-1-165") or a salt thereof.

[0042] In the present invention, the above-mentioned CDK8 / 19 inhibitor and its salt may be a non-solvate or a solvate. Solvates can be formed using solvents such as ethanol and water. Solvates containing water as a solvent are hydrates. Among hydrates, in addition to hydrates that conform to stoichiometric hydrates, hydrates containing various amounts of water are also included.

[0043] In addition, examples of the "salt" in the present invention include salts with inorganic bases, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids. Preferred examples of the salt with an inorganic base include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts, magnesium salts and barium salts; and aluminum salts. Preferred examples of the salt with an organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N′-dibenzylethylenediamine and the like. Preferred examples of the salt with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. Preferred examples of the salt with an organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like. Preferred examples of the salt with a basic amino acid include salts with arginine, lysine, ornithine, and the like. Preferred examples of the salt with an acidic amino acid include salts with aspartic acid, glutamic acid, and the like. Among these salts, pharmaceutically acceptable salts are preferred.

[0044] The CDK8 / 19 inhibitors in the present invention are not limited to the above compounds. Antisense oligonucleotides or siRNA of CDK8 / 19 mRNA, antibodies binding to CDK8 / 19, dominant negative CDK8 / 19 mutants, etc. can also be used as CDK8 / 19 inhibitors.

[0045] The above-mentioned CDK8 / 19 inhibitors can be used those that are commercially available or synthesized according to a known method.

[0046] The "ALK5 inhibitor" used in the present invention is not particularly limited as long as it is non-mutagenic and has ALK5 (activin receptor-like kinase 5) inhibitory activity, and all factors that directly or indirectly inhibit ALK5 function except ALK5iII can be used.

[0047] In the present invention, the "ALK5 inhibitor" can be a conventionally known inhibitor, and more specifically, there is no particular limitation, and examples thereof include the following compounds or salts thereof. In addition, as long as these compounds have ALK5 inhibitory activity, they may have one or more substituents, and may also have a partial structure (substituent, ring, etc.) changed.

[0048]

Table 3

[0049] In addition, the ALK5 inhibitors that can be used in the present invention are not particularly limited, and for example, the following compounds or their salts can be used: Galunisertib (LY2157299) (Cas. No. 700874-72-2), SB505124 (Cas. No. 694433-59-5), LY364947 (Cas. No. 396129-53-6), K02288 (Cas. No. 1431985-92-0), LDN-21 4117(Cas.No.1627503-67-6), SD-208(Cas.No.627536-09-8), ML347(LDN193719)(Cas.No.1062368-49-3), LDN-212854(Cas.No.1432597-26-6), DMH1(Cas.No.1206711-16-1), Pirfenidone(Cas.No.53179-13-8), LY 3200882(Cas.No.1898283-02-7), Alanolactone(Cas.No.546-43-0), SIS3(Cas.No.1009104-85-1), Hesper etin(Cas.No.520-33-2), Dorsomorphin(BML-275)(Cas.No.866405-64-3), ALK2-IN-2(Cas.No.2254409-25-9 ), San78-130 (Cas. No. 66018-45-9), TGFβRI-IN-1 (Cas. No. 1950628-94-0), Crizotinib-d5 (Cas. No. 1395950- 48-7), ALK-IN-1 (Cas. No. 1197958-12-5), A-77-01 (Cas. No. 607737-87-1), TAE-684 (Cas. No. 761439-42-3), D 4476 (Cas. No. 301836-43-1), Galunisertib (Cas. No. 700874-72-2), SM16 (Cas. No. 614749-78-9), N-Acetylpuromycin (Cas. No. 22852-13-7), TGF-βRI KinaseInhibitor IX(Cas.No.301836-41-9), TGF-βRI Kinase Inhibitor VII(Cas.No.666729-57-3), IM-412 (3-(2-chlorophenyl)-1,7-dimethyl-1H-imidazole [2,1-f] purine-2,4 (3H, 8H) -dione), TSP-1 (LSKL, Thrombospondin inhibitor) (Cas. No. 283609-79-0), R268712 (Cas. No. 879487-87-3), LY2109761 (Cas. No. 700874-71-1), GW788388 (Cas. No. 452342-67- 5), LDN-193189 (Cas. No. 1062368-24-4), A-83-01 (Cas. No. 909910-43-6), ITD1 (Cas. No. 1099644-42-4), IWR1 (Cas. No. 1127442-82-3), YN968D1 (Cas. No. 811803-05-1), BFH-772 (Cas. No. 890128-81-1), Regorafenib (Cas. No. 755037-03-7). .

[0050] Preferably, the ALK5 inhibitor that can be used in the present invention is 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline or a salt thereof.

[0051] In the present invention, the ALK5 inhibitor and its salt may be a non-solvate or a solvate. Examples of the "solvate" and "salt" include the solvates and salts defined above.

[0052] The ALK5 inhibitors in the present invention are not limited to the above compounds. Antisense oligonucleotides and siRNA against mRNA of ALK5 and its receptor, antibodies binding to ALK5 and its receptor, dominant negative ALK5 mutants and dominant negative ALK5 receptor mutants can also be used as ALK5 inhibitors.

[0053] The above-mentioned ALK5 inhibitors may be those commercially available or synthesized according to a known method.

[0054] Preferably, the culture medium of the present invention contains 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4 -([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline and their salts and one or more CDK8 / 19 inhibitors selected from 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile and their salts. More preferably, the culture medium of the present invention contains a combination of 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide or a salt thereof as an ALK5 inhibitor and 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile or 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide or a salt thereof as a CDK8 / 19 inhibitor.

[0055] The "insulin-positive cell population" in the present invention means a cell population comprising insulin-positive cells induced by differentiation of pluripotent stem cells. "Insulin-positive cells" means cells characterized by the expression of insulin markers. "Insulin-positive cells" may be cells expressing a marker of NK6 homeobox 1 (NKX6.1), preferably cells expressing markers of both insulin and NKX6.1 (i.e., insulin-positive and NKX6.1-positive cells). Insulin-positive cells may include β cells.

[0056] The "insulin-positive cell population" in the present invention can be obtained by culturing a pancreatic precursor cell population induced by differentiation of pluripotent stem cells or a cell population in a subsequent differentiation stage in a culture medium that does not contain ALK5iII and contains factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity to differentiate them. In addition to insulin-positive cells, the insulin-positive cell population may also include other cells (e.g., endocrine precursor cells; other pancreatic hormone-producing cells (α cells or δ cells, etc.) that express at least one marker of glucagon, somatostatin, and pancreatic polypeptide; CHGA-positive cells; Ki67-positive cells; CHGA-negative cells, etc.).

[0057] In the present invention, "pancreatic precursor cell group or cell group at a subsequent differentiation stage" means a pancreatic precursor cell group, an endocrine precursor cell group, or an insulin-positive cell group, or two or more cell groups selected from a pancreatic precursor cell group, an endocrine precursor cell group, and an insulin-positive cell group. Preferably, "pancreatic precursor cell group or cell group at a subsequent differentiation stage" in the present invention means a pancreatic precursor cell group or an endocrine precursor cell group, or both a pancreatic precursor cell group and an endocrine precursor cell group.

[0058] In this specification, "pluripotency" means the ability to differentiate into various tissues or cells with different morphologies or functions, and the ability to differentiate into cells of any of the three germ layers. "Pluripotency" cannot differentiate into a blastoderm, and therefore, from the perspective of not having the ability to form an individual, it is distinguished from "totipotency" which can differentiate into all tissues of an organism including a blastoderm.

[0059] In this specification, "multipotency" means the ability to differentiate into multiple cells of a limited number of layers. For example, mesenchymal stem cells, hematopoietic stem cells, and neural stem cells are multipotent, not pluripotent.

[0060] In this specification, "pluripotent stem cells" refer to embryonic stem cells (ES cells) and cells that potentially have the same differentiation pluripotency as ES cells, that is, the ability to differentiate into various tissues of an organism (entoderm, mesoderm, ectoderm). "Induced pluripotent stem cells" (also referred to as "iPS cells" in this specification) can be cited as cells that have the same differentiation pluripotency as ES cells. Preferably, in the present invention, pluripotent stem cells are human pluripotent stem cells.

[0061] If mouse ES cells are used as "ES cells", various mouse ES cell lines established by inGenious, RIKEN (RIKEN), etc. can be used; if human ES cells are used as "ES cells", various human ES cell lines established by the National Institutes of Health (NIH), RIKEN, Kyoto University, and Cellartis can be used. For example, CHB-1 to CHB-12 strains, RUES1 strain, RUES2 strain, HUES1 to HUES28 strains, etc. of NIH; H1 strain and H9 strain of WiCell Research Institute; KhES-1 strain, KhES-2 strain, KhES-3 strain, KhES-4 strain, KhES-5 strain, SSES1 strain, SSES2 strain, SSES3 strain, etc. of RIKEN can be used as ES cell lines.

[0062] “Induced pluripotent stem cells” refer to cells obtained by introducing specific factors (nuclear reprogramming factors) into mammalian somatic cells or undifferentiated stem cells and reprogramming them. Currently, there are various types of "induced pluripotent stem cells". In addition to the iPS cells established by Yamanaka et al. by introducing the four factors Oct3 / 4, Sox2, Klf4 and c-Myc into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), there are also iPS cells derived from human cells established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S., et al., Cell, (2007) 131: 861-872.), Nanog-iPS cells established by screening with Nanog expression as an indicator after the introduction of the above four factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.), iPS cells produced by a method that does not include c-Myc (Nakagawa M, Yamanaka S., et al., Nature Biotechnology, (2008) 26, 101-106), iPS cells established by introducing six factors by a virus-free method (Okita K et al., Nat. Methods 2011 May; 8(5): 409-12, Okita K et al., Stem Cells. 31(3): 458-66.). In addition, the following can also be used: induced pluripotent stem cells established by introducing four factors, OCT3 / 4, SOX2, NANOG and LIN28, produced by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920), induced pluripotent stem cells produced by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), induced pluripotent stem cells produced by Sakurada et al. (Japanese Patent Application Laid-Open No. 2008-307007), etc.

[0063] In addition, all published papers (e.g., Shi Y., Ding S. et al., Cell Stem Cell, (2008) Vol 3, Issue 5, 568-574; Kim JB., Scholer HR. et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, DA. et al., Nature Biotechnology, (2008) 26, No 7, 795-797) or patents (e.g., Japanese Patent Application Laid-Open No. 2008-307007, Japanese Patent Application Laid-Open No. 2008-283972, US2008 / 2336610, US2009 / 047263, WO 2007 / 069666, WO 2008 / 118220, WO 2008 / 124133, WO Any of the induced pluripotent stem cells known in the art described in WO 2008 / 151058, WO 2009 / 006930, WO 2009 / 006997, WO 2009 / 007852).

[0064] As the induced pluripotent cell line, various iPS cell lines established by NIH, RIKEN (RIKEN), Kyoto University, etc. can be used. For example, in the case of human iPS cell lines, examples include: HiPS-RIKEN-1A, HiPS-RIKEN-2A, HiPS-RIKEN-12A, and Nips-B2 of RIKEN; Ff-WJ-18, Ff-I01s01, Ff-I01s02, Ff-I01s04, Ff-I01s06, Ff-I14s03, Ff-I14s04, QHJI01s01, QHJI01s04, QHJI14s03, QHJI14s04, 253G1, 201B7, 409B2, 454E2, 606A1, 610B1, and 648A1 of Kyoto University; and MyCell iPS Cells (21525.102.10A) strain, MyCell iPS Cells (21526.101.10A) strain, etc.

[0065] The "pancreatic precursor cell population" in this specification refers to a cell population comprising pancreatic precursor cells. In this specification, pancreatic precursor cells are characterized by the expression of NKX6.1 as a marker (i.e., NKX6.1 positive). Pancreatic precursor cells may further express at least one marker among PDX-1, PTF-1α, GATA4 and SOX9. Preferably, pancreatic precursor cells are characterized by the expression of NKX6.1 and PDX-1 (i.e., NKX6.1 positive and PDX-1 positive).

[0066] In one embodiment, the "pancreatic precursor cell population" of the present invention is a cell population corresponding to the culture after completion of step 4) or the culture in step 5) in the step of inducing differentiation of pluripotent stem cells into pancreatic β cells described in detail below.

[0067] In the "pancreatic precursor cell group" of the present invention, the pancreatic precursor cells are contained in a ratio of 30% or more, preferably 40% or more, more preferably 50% or more, further preferably 60% or more, and further preferably 70% or more. In addition to pancreatic precursor cells, the pancreatic precursor cell group may also contain other cells (e.g., endocrine precursor cells, insulin-positive cells, Ki67-positive cells, CHGA-negative cells, etc.).

[0068] In addition, the proportion of specific cells in the cell population described in the present specification can be determined based on a known method capable of counting the number of cells, such as flow cytometry.

[0069] The "endocrine precursor cell group" in this specification refers to a cell group containing endocrine precursor cells. In this specification, endocrine precursor cells refer to cells characterized by the expression of at least one marker of CHGA, NeuroD and NGN3 and the non-expression of markers of the pancreas-associated hormone system (e.g., insulin, etc.). Endocrine precursor cells may also express markers such as PAX-4, NKX2.2, Islet-1, and PDX-1.

[0070] In one embodiment, the "endocrine precursor cell population" of the present invention is a cell population corresponding to the culture after step 5) or the culture in step 6) in the step of inducing differentiation of pluripotent stem cells into pancreatic β cells described in detail below.

[0071] In the "endocrine precursor cell group" of the present invention, the endocrine precursor cells are contained in a ratio of 30% or more, preferably 40% or more, more preferably 50% or more, further preferably 60% or more, and further preferably 70% or more. In addition to the endocrine precursor cells, the endocrine precursor cell group may also contain other cells (e.g., pancreatic precursor cells, insulin-positive cells, Ki67-positive cells, CHGA-negative cells, etc.).

[0072] It is known that in the process of differentiation from pluripotent stem cells into insulin-positive cells, cells with different characteristics appear according to the differentiation stage (WO 2009 / 012428, WO 2016 / 021734). For example, in this differentiation stage, they can be roughly divided into pluripotent stem cells, definitive endoderm cells, gastrointestinal cells, posterior foregut cells, pancreatic precursor cells, endocrine precursor cells, and insulin-positive cells in the order of relative undifferentiation.

[0073] The pancreatic precursor cell group or the cell group at the subsequent differentiation stage can be obtained using a known method for inducing the differentiation of pluripotent stem cells into insulin-positive cells. That is, the cell group at each target differentiation stage can be obtained using the following differentiation induction steps: Step 1) inducing differentiation of pluripotent stem cells into definitive endoderm cells; Step 2) inducing the definitive endoderm cells to differentiate into gastrointestinal cells; Step 3) inducing differentiation of gastrointestinal cells into posterior foregut cells; Step 4) inducing differentiation of posterior foregut cells into pancreatic progenitor cells; Step 5) inducing differentiation of pancreatic precursor cells into endocrine precursor cells; and Step 6) Inducing differentiation of endocrine precursor cells into insulin-positive cells. Each step will be described below, but the differentiation induction of each cell is not limited to these methods.

[0074] Step 1) Differentiation into definitive endoderm cells First, pluripotent stem cells are differentiated into definitive endoderm cells. Methods for inducing definitive endoderm from pluripotent stem cells are well known, and any of these methods may be used. Preferably, pluripotent stem cells are cultured in a medium containing activin A, more preferably in a medium containing activin A, a ROCK inhibitor, and a GSK3β inhibitor, so as to differentiate into definitive endoderm cells. The number of cells at the start of culture is not particularly limited, but is 22,000 cells / cm 2 ~150,000 cells / cm 2 , preferably 22000 cells / cm 2 ~100,000 cells / cm 2 , more preferably 22000 cells / cm 2 ~80,000 cells / cm 2 The culture time is 1 to 4 days, preferably 1 to 3 days, and particularly preferably 3 days.

[0075] The culture temperature is not particularly limited, and is performed at 30° C. to 40° C. (for example, 37° C.). The carbon dioxide concentration in the culture container is, for example, about 5%. The culture can be performed in two-dimensional culture or three-dimensional culture.

[0076] The culture medium used in this step can be: RPMI 1640 medium, MEM medium, iMEM medium, DMEM / F12 medium, modified MEM Zinc Option medium, modified MEM / 1% B-27 / PenisilinStreptomycin medium, MCDB131 / 20mM Glucose / NaHCO3 / FAF-BSA / ITS-X / GlutaMAX TM / Ascorbic acid / Penisilin Streptomycin medium and other basic culture media used to culture mammalian cells.

[0077] The concentration of activin A in the culture medium is usually 30 ng / mL to 200 ng / mL, preferably 50 ng / mL to 150 ng / mL, more preferably 70 ng / mL to 120 ng / mL, particularly preferably about 100 ng / mL. In another embodiment, activin A may be included in the culture medium at a low dosage, for example, 5 ng / mL to 100 ng / mL, preferably 5 ng / mL to 50 ng / mL, more preferably 5 ng / mL to 10 ng / mL. In yet another embodiment, the concentration of activin A in the culture medium is about 0.1 ng / mL to 100 ng / mL, preferably about 1 ng / mL to 50 ng / mL, and more preferably about 3 ng / mL to 10 ng / mL.

[0078] The concentration of the GSK3β inhibitor in the culture medium is appropriately set depending on the type of the GSK3β inhibitor used. For example, when CHIR99021 is used as the GSK3β inhibitor, the concentration is usually 2 μM to 5 μM, preferably 2 μM to 4 μM, and particularly preferably about 3 μM.

[0079] The concentration of the ROCK inhibitor in the culture medium is appropriately set depending on the type of ROCK inhibitor used. For example, when Y27632 is used as a ROCK inhibitor, the concentration is usually 5 μM to 20 μM, preferably 5 μM to 15 μM, and particularly preferably about 10 μM.

[0080] Insulin may be further added to the culture medium. Insulin may be contained in the culture medium in an amount of 0.01 μM to 20 μM, preferably 0.1 μM to 10 μM, and more preferably 0.5 μM to 5 μM. The concentration of insulin in the culture medium may be the concentration of insulin contained in the added B-27 supplement, but is not limited thereto.

[0081] In a specific embodiment, after culturing for 1 day in a medium containing activin A, a ROCK inhibitor, and a GSK3β inhibitor, the culture is further cultured for 2 days while the medium is exchanged every day with a medium containing only activin A. Alternatively, the pluripotent stem cells can be produced by first culturing in a medium containing 0.01 μM to 20 μM insulin in the presence of a low dose of activin A and then second culturing in a medium without insulin.

[0082] Step 2) Differentiation into gastrointestinal cells The definitive endoderm cells obtained in step 1) are further cultured in a culture medium containing growth factors to induce differentiation into gastrointestinal cells. The culture time is 2 to 8 days, preferably about 4 days.

[0083] The culture temperature is not particularly limited, and is performed at 30° C. to 40° C. (for example, 37° C.). The carbon dioxide concentration in the culture container is, for example, about 5%. The culture can be performed in two-dimensional culture or three-dimensional culture.

[0084] The medium may be a basal medium for culturing mammalian cells in the same manner as in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. may be appropriately added to the medium.

[0085] As the growth factor, EGF, KGF, and FGF10 are preferred, EGF and / or KGF are more preferred, and KGF is further preferred.

[0086] The concentration of the growth factor in the culture medium is appropriately set according to the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / mL to 1000 ng / mL (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / mL to 1000 ng / mL (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / mL to 1000 ng / mL (i.e., about 0.6 nM to 58 nM). For example, when KGF is used as a growth factor, the concentration is usually 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL.

[0087] Step 3) Differentiation into posterior foregut cells The gastrointestinal cells obtained in step 2) are further cultured in a culture medium containing growth factors, cyclopamine, noggin, etc., and differentiated into posterior foregut cells. The culture time is 1 to 5 days, preferably about 2 days. The culture can be carried out by two-dimensional culture or three-dimensional culture.

[0088] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0089] The medium may be a basal medium for culturing mammalian cells in the same manner as in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. may be appropriately added to the medium.

[0090] As the growth factor, EGF, KGF, and FGF10 are preferred, EGF and / or KGF are more preferred, and KGF is further preferred.

[0091] The concentration of the growth factor in the culture medium is appropriately set according to the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / mL to 1000 ng / mL (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / mL to 1000 ng / mL (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / mL to 1000 ng / mL (i.e., about 0.6 nM to 58 nM). For example, when KGF is used as a growth factor, the concentration is usually 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL.

[0092] The concentration of cyclopamine in the medium is not particularly limited, but is usually 0.5 μM to 1.5 μM, preferably 0.3 μM to 1.0 μM, and particularly preferably about 0.5 μM.

[0093] The concentration of Noggin in the culture medium is not particularly limited, but is usually 10 ng / mL to 200 ng / mL, preferably 50 ng / mL to 150 ng / mL, and particularly preferably about 100 ng / mL.

[0094] Step 4) Differentiation into pancreatic progenitor cells The posterior foregut cells obtained in step 3) are further cultured in a culture medium containing a factor having CDK8 / 19 inhibitory activity, preferably in a culture medium containing a factor having CDK8 / 19 inhibitory activity and a proliferation factor, and differentiated into pancreatic progenitor cells. The culture time is 2 to 10 days, preferably about 5 days. The culture can be performed by two-dimensional culture or three-dimensional culture.

[0095] In the case of two-dimensional culture, according to previous reports (Toyoda et al., Stem Cell Research (2015) 14, 185-197), the posterior foregut cells obtained in step 3) were treated with 0.25% trypsin-EDTA solution, dispersed in the solution by pipetting to obtain a cell dispersion, the obtained dispersion was centrifuged, the recovered cells were resuspended in a small amount of fresh culture medium, and this cell suspension was re-inoculated into the new culture medium in step 4).

[0096] The medium may be a basal medium for culturing mammalian cells in the same manner as in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. may be appropriately added to the medium.

[0097] The aforementioned various compounds or salts thereof can be used as factors having CDK8 / 19 inhibitory activity, and the amount added to the culture medium is appropriately determined according to the compound or salt used, usually about 0.00001 μM to 5 μM, preferably 0.00001 μM to 1 μM. The concentration of the factor having CDK8 / 19 inhibitory activity in the culture medium is preferably a concentration that achieves 50% or more of the inhibitory activity on CDK8 / 19.

[0098] As the growth factor, EGF, KGF, and FGF10 are preferred, KGF and / or EGF are more preferred, and KGF and EGF are further preferred.

[0099] The concentration of the growth factor in the culture medium is appropriately set according to the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / mL to 1000 ng / mL (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / mL to 1000 ng / mL (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / mL to 2000 ng / mL (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / mL to 1000 ng / mL (i.e., about 0.6 nM to 58 nM). For example, when KGF and EGF are used as growth factors, the concentration of EGF is usually 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL; the concentration of KGF is usually 10 ng / mL to 200 ng / mL, preferably 50 ng / mL to 150 ng / mL, and particularly preferably about 100 ng / mL.

[0100] The first day of culturing in step 4) may be performed in the presence of a ROCK inhibitor, and thereafter culturing may be performed in a medium not containing a ROCK inhibitor.

[0101] In addition, the culture medium may also contain a protein kinase C (PKC) activator. PDBu (PKC activator II), TPB (PKC activator V), etc. can be used as the PKC activator, but are not limited thereto. The PKC activator is added at a concentration of about 0.1 ng / mL to 100 ng / mL, preferably about 1 ng / mL to 50 ng / mL, and more preferably about 3 ng / mL to 10 ng / mL.

[0102] Furthermore, dimethyl sulfoxide and / or activin (1 ng / mL to 50 ng / mL) may be added to the culture medium.

[0103] In any step, in addition to the above-mentioned ingredients, serum substitutes (e.g., B-27 supplement, ITS-G) may be added to the culture medium. In addition, amino acids, L-glutamine, GlutaMAX (product name), non-essential amino acids, vitamins, nicotine amide, antibiotics (e.g., antibiotic-antifungal, penicillin, streptomycin or a mixture thereof), antibacterial agents (e.g., amphotericin B), antioxidants, pyruvic acid, buffers, inorganic salts, etc. may also be added as needed. When antibiotics are added to the culture medium, their concentration in the culture medium is generally 0.01% to 20% by weight, preferably 0.1% to 10% by weight. Cultivation may be performed by two-dimensional culture or three-dimensional culture.

[0104] In addition, when cell culture is two-dimensional culture, feeder cells are not used, and culture is carried out by adhesion. During cultivation, culture vessels such as cell culture sheets such as dish, flask, microplate, OptiCell (product name) (Nunc company) are used. Preferably, culture vessel is treated to improve the surface of the adhesiveness (hydrophilicity) with cell, or collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin, matrigel (for example, BD matrigel (Beckton Dickinson, Japan), vitronectin etc. are coated thereon with the matrix for cell adhesion. Preferably, the culture vessel coated with type I collagen, matrigel, fibronectin, vitronectin or poly-D-lysine etc. is used as culture vessel, more preferably, the culture vessel coated with matrigel or poly-D-lysine is used as culture vessel.

[0105] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0106] The pancreatic progenitor cells obtained in step 4) can be further purified using glycoprotein 2 (GP2), a known surface marker, etc. The purification can be performed by a known method, for example, using beads to which an anti-GP2 antibody is immobilized.

[0107] Step 5) Differentiation into endocrine precursor cells The pancreatic precursor cells obtained in step 4) are further cultured in a culture medium containing proliferation factors to induce differentiation into endocrine precursor cells. The culture can be performed by two-dimensional culture or three-dimensional culture. In the case of two-dimensional culture, the pancreatic precursor cells obtained in step 4) are treated with a 0.25% trypsin-EDTA solution, dispersed in the solution by pipetting to obtain a cell dispersion, the obtained dispersion is centrifuged, the recovered cells are resuspended in a small amount of fresh culture medium, and the cell suspension is re-inoculated into the new culture medium of step 5). The culture time is 2 to 3 days, preferably about 2 days.

[0108] The culture medium can be a basic culture medium for culturing mammalian cells in the same manner as in step 1). According to previous reports (Nature Biotechnology 2014; 32: 1121-1133), SANT1, retinoic acid, ALK5 inhibitor II, T3, and LDN are added to the culture medium. Furthermore, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, etc. can be added to the culture medium in appropriate amounts. In addition, in the present invention, in step 5), by using the above-mentioned culture medium containing factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, the ALK5 inhibitor II previously used in step 5) is substantially not contained, and preferably is not used.

[0109] The culture is performed by non-adhesive culture without using feeder cells. During the culture, a dish, flask, microplate, multi-well plate (Nunc) or a bioreactor is used. The culture container is preferably surface treated to reduce adhesion to the cells.

[0110] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0111] The endocrine precursor cells obtained in step 5) can be further purified using glycoprotein 2 (GP2), a known surface marker, etc. The purification can be performed by a known method, for example, using beads to which anti-GP2 antibodies are immobilized.

[0112] Step 6) Differentiation into insulin-positive cells The endocrine precursor cells obtained in step 5) are further cultured in a culture medium containing growth factors to induce differentiation into insulin-positive cells. The culture time is 10 to 30 days, preferably about 10 to 20 days.

[0113] The culture medium can be a basal medium for culturing mammalian cells in the same manner as in step 1). According to a previous report (Nature Biotechnology 2014; 32: 1121-1133), ALK5 inhibitor II, T3, LDN, γ-secretase inhibitor XX, γ-secretase inhibitor RO, N-cysteine, AXL inhibitor, and ascorbic acid are added to the culture medium. Furthermore, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, etc. can be added to the culture medium in appropriate amounts. For example, ALK5 inhibitor II, T3, LDN, γ-secretase inhibitor RO, and ascorbic acid can be added to the culture medium, or T3, ALK5 inhibitor II, ZnSO4, heparin, N-acetylcysteine, Trolox, and R428 can be added to the culture medium. In the present invention, in step 6), by using the culture medium containing the factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, the ALK5 inhibitor II conventionally used in step 6) is substantially not contained, and preferably is not used.

[0114] Cultivation can be carried out by two-dimensional culture or three-dimensional culture. Cultivation does not use feeder cells. In the case of three-dimensional culture, it is carried out by non-adhesive culture. During cultivation, a dish, flask, microplate, multi-well plate (Nunc company) or a bioreactor is used. Preferably, the culture container is surface treated to reduce adhesion to the cells.

[0115] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0116] In the present invention, the "medium containing a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity" may contain a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity in any amount capable of inhibiting ALK5 activity and CDK8 / 19 activity. When the factor is a combination of multiple factors including an ALK5 inhibitor and a CDK8 / 19 inhibitor, the ALK5 inhibitor and the CDK8 / 19 inhibitor may be contained in any amount capable of inhibiting the activity of each target.

[0117] For example, the ALK5 inhibitor may be contained in the culture medium in an amount of 10 μM and below, 5 μM and below, 4 μM and below, 3 μM and below, 2 μM and below, or 1 μM and below. The lower limit of the added amount is not particularly limited, and may be 0.1 nM and above, 0.2 nM and above, 0.3 nM and above, 0.4 nM and above, or 0.5 nM and above. For example, the added amount of the ALK5 inhibitor is 10 μM and below and 0.1 nM and above, preferably 5 μM and below and 0.1 nM and above, more preferably 1 μM and below and 0.1 nM and above, for example, less than 4 μM and greater than or equal to 0.1 nM, 3 μM and below and 0.3 nM and above.

[0118] In addition, for example, the CDK8 / 19 inhibitor may be contained in the culture medium in an amount of 10 μM and below, 5 μM and below, 4 μM and below, 3 μM and below, 2 μM and below, or 1 μM and below, and the lower limit of the added amount is not particularly limited, and may be 0.1 nM and above, 0.2 nM and above, 0.3 nM and above, 0.4 nM and above, or 0.5 nM and above. For example, the amount of the CDK8 / 19 inhibitor added is 10 μM and below and 0.1 nM and above, preferably 5 μM and below and 0.1 nM and above, more preferably 1 μM and below and 0.1 nM and above, for example, less than 1 μM and greater than or equal to 0.1 nM.

[0119] In addition, the pancreatic precursor cell group obtained by differentiation induction of pluripotent stem cells or the cell group in the differentiation stage thereafter can be cultured in a culture medium containing a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity for at least 12 hours, preferably 24 hours or more, 2 days or more, 4 days or more, 8 days or more, 10 days or more, or 15 days or more. The culture in the culture medium containing the factor is preferably carried out for 4 days or more. The culture medium containing the factor can also be exchanged, and can be exchanged with a culture medium having the same composition as before the exchange or a culture medium having a different composition to which the factor is added according to the culture plan.

[0120] The pancreatic precursor cell group obtained by differentiation induction of pluripotent stem cells or the cell group in the differentiation stage thereafter can be cultured in a culture medium containing factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, and the step of differentiating into a target cell group can be carried out. Here, "culture and differentiation in a culture medium containing factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity" also includes the case where the step of culturing in a culture medium containing the factors and the step of differentiating into a target cell group are carried out at the same time, the case where the step of differentiating into a target cell group is carried out after culturing in a culture medium containing the factors, and the case where the step of differentiating into a target cell group is carried out after carrying out the step of differentiating. Therefore, the culture medium containing factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity can be different from the culture medium used to differentiate the cell group, and the factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity can be further added to the culture medium used in the differentiation step.

[0121] In one embodiment of the present invention, in the step of inducing insulin-positive cells by differentiation from pluripotent stem cells, a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity is included in the culture medium after step 5 (i.e., the culture medium of step 5, or the culture medium of step 6, or the culture medium of step 5 and the culture medium of step 6) to act on the cells.

[0122] The insulin-positive cell group obtained by the present invention can be differentiated, induced or matured into a cell group containing pancreatic β cells (hereinafter, described as "pancreatic β cell group"). "Pancreatic β cells" in this specification refer to cells that are more mature than "insulin-positive cells", specifically, cells that express at least one of MAFA, UCN3 and IAPP, which are markers of pancreatic β cell maturation, or are characterized by an increased insulin secretion response caused by glucose stimulation. In addition to pancreatic β cells, the pancreatic β cell group may also include other cells (e.g., insulin-positive cells, Ki67-positive cells, CHGA-negative cells, etc.).

[0123] The pancreatic β cell population can be obtained by differentiating and maturing the insulin-positive cell population. The pancreatic β cell population is preferably obtained by differentiating and maturing the insulin-positive cell population in an animal body.

[0124] The "animal" is preferably a mammal, and examples thereof include humans, non-human primates, pigs, cows, horses, sheep, goats, llamas, dogs, cats, rabbits, mice, guinea pigs, etc., and preferably humans.

[0125] Transplantation is preferably performed in an area in the body where the cell population can be fixed at a certain position, for example, it can be performed subcutaneously, intraperitoneally, in the peritoneal epithelium, omentum, adipose tissue, muscle tissue, or under the capsule of organs such as the pancreas and kidney. The number of cells to be transplanted can vary depending on important factors such as the differentiation stage of the transplanted cells, the age and weight of the transplanted subject, the size of the transplanted site, the severity of the disease, and is not particularly limited. For example, it can be 10×10 4 cells~10×10 11 The transplanted cell population can be induced to differentiate into a target cell population, preferably a pancreatic β cell population, in an in vivo environment, and then can be recovered or directly left in the body.

[0126] During transplantation, the cell population may be embedded in a gel containing a biocompatible material for transplantation. For example, the cell population embedded in a gel containing a biocompatible material may be enclosed in a device such as a capsule, a bag or a chamber and then transplanted into the body.

[0127] The term "embedding" used herein means that an endocrine precursor cell population or a cell population at a subsequent differentiation stage is dispersed and contained in a gel containing a biocompatible material.

[0128] The "biocompatible material" in this specification means any material that does not induce a significant immune response or harmful biological response (e.g., toxic reaction, coagulation, etc.) when transplanted into a living body and left in for a short or long term. In addition, the "biocompatible material" is preferably a biodegradable material. Such materials include: polylactic acid (PLA), polycaprolactone (PCL), polyurethane (PU), polyethylene glycol (PEG), polyhydroxyethyl methacrylate, polyglycolic acid (PGA), polylactic acid-glycolic acid copolymer (PLGA), poly (3-hydroxybutyrate-hydroxyvalerate copolymer) (PHBV), poly (ethylene-vinyl acetate copolymer) (PEVA), polyacrylamide, polyethylene oxide, polyethyleneimine, polyhydroxybutyric acid, poly (N-vinyl pyrrolidone), polyvinyl alcohol, polyfumaric acid Acrylate, polyacrylic acid, poly e-caprolactone, polymethacrylic acid, polyvinylidene fluoride (PVDF), pectic acid, hyaluronic acid, heparan sulfate, chondroitin sulfate, heparan sulfate proteoglycan, heparin, chitin, chitosan, xanthan gum, carboxymethyl cellulose, carboxymethyl chitosan, alginate, alginate, collagen, cellulose, fibroin, keratin, gelatin, fibrin, pullulan, laminin, gellan gum, silicon, urethane, elastin, etc. and their deformations and combinations thereof. If necessary, the surface of the "biocompatible material" can also be subjected to surface modification (for example, by coating a matrix for cell adhesion (collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin, matrigel, vitronectin, etc.)), or by using a functional group known to control cell proliferation, differentiation or function (for example, amino, carboxyl, hydroxyl, methacrylic, acrylic, etc.) to make cell adhesion possible. In certain embodiments, alginate or alginate esters may be suitably used as the "biocompatible material".

[0129] The alginate may be any water-soluble salt, and may be a metal salt, an ammonium salt, etc. For example, sodium alginate, calcium alginate, ammonium alginate, etc. may be used appropriately.

[0130] Alginate (also known as propylene glycol alginate) is a derivative in which propylene glycol is esterified with the carboxyl group of alginic acid.

[0131] The ratio of mannuronic acid to guluronic acid (M / G ratio) contained in alginate is arbitrary. Generally speaking, when M>G, a soft gel can be formed, and when M<G, a firm gel can be formed. In the present invention, alginate containing guluronic acid in a ratio of 10% to 90%, 20% to 80%, 30% to 70%, or 40% to 60% can be used.

[0132] The gel using alginate or alginate ester can be produced according to a known method (WO 2010 / 032242, WO 2011 / 154941), and can be obtained by adding a crosslinking agent to an alginate or alginate ester solution and causing the solution to gel.

[0133] The solvent may contain 0.05% to 10% by weight, preferably 0.1% to 5% by weight, and more preferably 0.5% to 3% by weight of alginate or alginate ester. The solvent may be any solvent that can dissolve alginate or alginate ester, and water, physiological saline, etc. may be used.

[0134] The cross-linking agent is not particularly limited, as long as it can gel the solution of alginate or alginate ester, and a polyvalent metal cation can be used. The polyvalent metal cation is preferably a divalent metal cation, more preferably a calcium ion, a strontium ion, or a barium ion. The cross-linking agent can be used in the form of a salt, and in the present invention, at least one selected from calcium chloride, strontium chloride, and barium chloride can be used as the cross-linking agent.

[0135] Nanofibers may be included in a gel containing alginate or alginate. Nanofibers are natural or synthetic fibers with a diameter in the nanometer range. Examples of natural nanofibers include: substances containing one or more polysaccharides such as collagen, cellulose, fibroin, keratin, gelatin, chitosan, etc. Examples of synthetic nanofibers include: polylactic acid (PLA), polycaprolactone (PCL), polyurethane (PU), poly(lactic acid-co-glycolic acid) (PLGA), poly(3-hydroxybutyrate-co-hydroxyvalerate) (PHBV), poly(ethylene-co-vinyl acetate) (PEVA), etc. Nanofibers may be included in a gel containing alginate in an amount of less than 1% by weight, for example, 0.9%, 0.8%, 0.7%, 0.6%, 0.5% or less by weight. The lower limit of the amount of nanofibers contained in a gel containing alginate or alginate is not particularly limited, and may be 0.05% or more by weight, preferably 0.1% or more by weight.

[0136] The embedding of the cell population in the gel containing alginate or alginate ester can be performed by any method without particular limitation, and can be performed, for example, by mixing the cell population in a solution of alginate or alginate ester and causing the mixture to gel.

[0137] The cell population can be selected from 1×10 4 cells / mL~1×10 9 cells / mL, preferably 1×10 7 cells / mL~1×10 8 The amount of cells / mL is contained in the alginate or alginate ester solution.

[0138] The gelation of the alginate or alginate solution containing the cell population can be carried out by adding a cross-linking agent to the solution. The amount of the cross-linking agent added can be selected from 0.1% to 5% by weight, for example, 0.1% to 1% by weight relative to the solution. The gelation can be carried out in a container having a prescribed structure and / or shape for cell culture or cell transplantation, or in a mold designed to obtain a gel suitable for the container.

[0139] Alternatively, it can be carried out by forming a gel capsule containing alginic acid according to a known method (WO 2010 / 010902). That is, it can be carried out by dropping a solution of alginate or alginate ester containing a cell group into a solution of a crosslinker. The size of the droplets can be adjusted according to the nozzle shape or the dropping method during the dropping, and the size of the gel capsule containing alginic acid can be specified. The dropping method is not particularly limited, but can be carried out by air spraying, airless spraying, electrostatic spraying, etc. The size of the gel capsule containing alginic acid is not particularly limited, and its diameter can be 5 mm and below, 1 mm and below, 500 μm and below. The crosslinker solution can contain a crosslinker selected from an amount of 0.1% to 10% by weight, for example, an amount of 0.1% to 5% by weight.

[0140] The insulin-positive cell population obtained by the present invention can be transplanted into an animal organism, and when differentiated in the animal organism, can be directly retained as cells that produce / secrete insulin.

[0141] The insulin-positive cell population obtained by the present invention can be used as a cell medicine for treating diabetes, especially type I diabetes, by being transplanted directly or encapsulated into the affected area.

[0142] Furthermore, the insulin-positive cell population obtained by the present invention may be a prodrug. In the present specification, a prodrug refers to a cell population that differentiates after being transplanted into a living body and changes into cells having a function of treating a disease.

[0143] The insulin-positive cell population obtained by the present invention has low toxicity (e.g., acute toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, carcinogenicity) and can be safely administered to mammals (e.g., mice, rats, hamsters, rabbits, cats, dogs, cattle, sheep, monkeys, humans) by directly or by mixing with a pharmaceutically acceptable carrier to form a pharmaceutical composition.

[0144] 3. Differentiation Medium The present invention provides a differentiation medium comprising a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, substantially free of ALK5iII, a pancreatic precursor cell population or a cell population at a subsequent differentiation stage, wherein the culture medium comprises a CDK8 / 19 inhibitor.

[0145] The differentiation medium of the present invention can be used for inducing differentiation of pancreatic precursor cell groups or cell groups in the subsequent differentiation stage. The differentiation medium of the present invention can be used in step 5) or step 6) of the above-mentioned method for inducing differentiation of pluripotent stem cells into insulin-positive cells.

[0146] The differentiation medium of the present invention is RPMI 1640 medium, MEM medium, iMEM medium, DMEM / F12 medium, modified MEM Zinc Option medium, modified MEM / 1% B-27 / Penisilin Streptomycin medium, MCDB131 / 20mM Glucose / NaHCO3 / FAF-BSA / ITS-X / GlutaMAX TM The basal medium used for culturing mammalian cells such as / ascorbic acid / PenisilinStreptomycin medium contains the above-mentioned factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity in any amount that can inhibit ALK5 activity and CDK8 / 19 activity. When the factor is a combination of multiple factors including ALK5 inhibitors and CDK8 / 19 inhibitors, the respective amounts of ALK5 inhibitors and CDK8 / 19 inhibitors contained in the culture medium are defined as above.

[0147] In addition to factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, the differentiation medium of the present invention further contains other factors such as growth factors, various inhibitors, serum replacements, antibiotics, vitamins, etc. required for step 5) and step 6). According to previous reports (Nature Biotechnology 2014; 32: 1121-1133), for example, SANT1, retinoic acid, T3, LDN, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, etc. can be added to the medium used in step 5) in a specified amount. In addition, T3, LDN, γ-secretase inhibitor XX, γ-secretase inhibitor RO, N-cysteine, AXL inhibitor, ascorbic acid, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, ZnSO4, heparin, N-acetylcysteine, Trolox, R428, etc. can be added to the medium used in step 6) in a specified amount.

[0148] The differentiation medium of the present invention does not substantially contain ALK5iII. “Substantially free of ALK5iII” means that ALK5iII is not contained in the medium in a manner that can exert any activity including ALK5 inhibitory activity, and does not necessarily mean that the medium does not contain any ALK5iII at all, but preferably means that the medium does not contain ALK5iII at all.

[0149] The differentiation medium of the present invention may be prepared by providing the basic medium, the factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, and the other factors described above in one form, or may be prepared by providing them in any combination or in a plurality of forms separately.

[0150] Hereinafter, the present invention will be described by way of examples, but the present invention is not limited to these examples. Example

[0151] Example 1: Evaluation of the mutagenicity of ALK5iII For 14 compounds including ALK5iII that are added to the differentiation medium during the existing differentiation induction of pluripotent stem cells into insulin-positive cell populations, the mutagenicity of each compound was analyzed using a bacterial mutagenicity prediction program (Derek and CASE Ultra) based on quantitative structure-activity relationship ((Quantitative)Structure Activity Relationship; (Q)SAR).

[0152] The results confirmed the mutagenicity structural alerts of five compounds, including ALK5iII. The five compounds with confirmed structural alerts were further subjected to Ames test to evaluate their mutagenicity.

[0153] The Ames test was conducted according to the known method, that is, for Salmonella typhimurium strains TA100, TA1535, TA98 and TA1537 and Escherichia coli WP2uvrA strain, seven different concentrations (78.1-5,000 μg / plate) of each compound were mixed, pre-cultured in a test tube for 20 minutes, and then semi-fluid agar was added to seed and solidified on a minimal glucose agar medium, and cultured at 37°C for 48 hours. It should be noted that since this experiment is intended to evaluate the mutagenicity of each compound in a cell culture system, rather than to evaluate the metabolites after metabolism by liver enzymes, the S9 part of rat liver is not included. As positive controls, strong mutagens 9-aminoacridine hydrochloride monohydrate (9-AA, Sigma-Aldrich) and ICR191 were used, and as negative controls, dimethyl sulfoxide was used. When the average value of the reverse mutant colonies of any strain is at least twice the average value of the negative control, it is judged to be positive.

[0154] The Ames test results showed that among the five compounds, only ALK5iII was positive for the TA1537 strain (without the S9 part), confirming its mutagenicity (see Table 4 below).

[0155]

Table 4

[0156] ALK5iII is a commercially available ALK5 inhibitor that is a naphthyridine derivative ( Figure 1 ). The TA1537 strain is known to be susceptible to intercalating agents that may be mutagenic. Therefore, to clarify whether the mutagenicity of ALK5iII is due to its planar structure or related to its ALK5 inhibitory ability, similar tests and evaluations were performed using a structural analog of ALK5iII (2-(3-(pyridin-3-yl)-1H-pyrazol-4-yl)quinoxaline and two other representative ALK5 inhibitors (SB525334 and SB431542).

[0157] The results showed that 2-(3-(pyridin-3-yl)-1H-pyrazol-4-yl)quinoxaline had no ALK5 inhibitory activity, but like ALK5iII, it showed positive results in the Ames test ( Figure 1 , Table 4). In contrast, other representative ALK5 inhibitors SB525334 and SB431542 showed no mutagenicity ( Figure 1 ). These results suggest that the mutagenicity of ALK5iII is most likely due to its naphthyridine-derived planar structure rather than its ALK5 inhibitory ability.

[0158] Example 2: Evaluation of off-target effects of ALK5iII In order to identify non-mutagenic ALK5 inhibitors that can be used to replace ALK5iII, which has been proven to be mutagenic, a total of 30 ALK5 inhibitors were selected from commercially available compounds and the compound library constructed by the present inventors, and their mutagenicity was analyzed using the same bacterial mutagenicity prediction program (Derek and CASE Ultra) as mentioned above.

[0159] The results showed that 20 of the 30 compounds did not have any known structural features associated with mutagenicity. Next, we tested whether these non-mutagenic ALK5 inhibitors could generate an insulin-positive cell population enriched in insulin-secreting cells.

[0160] In this verification method, the differentiation induction from iPS cells (Ff-I14-s04 strain) to pancreatic progenitor cell population was carried out according to the above steps 1)-4), previous reports (Stem Cell Research (2015) 14, 185-197), etc. The differentiation induction to insulin-positive cells was carried out according to the above steps 5) and 6).

[0161] The pancreatic progenitor cell population obtained by inducing differentiation of iPS cells was cultured for 2 days in a differentiation induction medium (modified MEM / 1% B-27 / Penisilin Streptomycin medium) containing ALK5iII (10 μM) or non-mutagenic ALK5 inhibitors (representative SB525334 (10 μM), SB431542 (10 μM), IN1130 (1 μM), EW-7197 (1 μM)) together with differentiation factors (SANT1, retinoic acid, T3, LDN, Wnt inhibitor, ROCK inhibitor, FGF2), and differentiated into an endocrine progenitor cell population.

[0162] Next, the cells were cultured for 7 days in a differentiation induction medium (modified MEM / 1% B-27 / PenisilinStreptomycin medium) containing ALK5iII (10 μM) or non-mutagenic ALK5 inhibitors (SB525334 (10 μM), SB431542 (10 μM), IN1130 (1 μM), or EW-7197 (1 μM)) together with differentiation factors (T3, LDN, γ-secretase inhibitor RO, FGF receptor 1 inhibitor PD-166866), according to previous reports (Nature Biotechnology 2014; 32: 1121-1133), together with T3, LDN, γ-secretase inhibitor RO, N-acetylcysteine, AXL inhibitor R428, ascorbic acid, ROCK inhibitor, ZnSO4, heparin, and Trolox, they were cultured for 4 days in MCDB131 / 20mM Glucose / NaHCO3 / FAF-BSA / ITS-X / Glutamax / Penisilin Streptomycin medium containing ALK5iII (10μM) or non-mutagenic ALK5 inhibitors (SB525334 (10μM), SB431542 (10μM), IN1130 (1μM) or EW-7197 (1μM) at specified concentrations, and differentiated into insulin-positive cell populations.

[0163] The number of insulin-positive and NKX6.1-positive cells and the number of CHGA-positive and PDX1-positive cells in the insulin-positive cell population obtained by the above method were counted by flow cytometry to obtain the cell rate of each cell population. In addition, as a control culture medium, a culture medium that did not contain either ALK5iII or a non-mutagenic ALK5 inhibitor was used.

[0164] The percentage of insulin-positive and NKX6.1-positive cells and the percentage of CHGA-positive and PDX1-positive cells in the insulin-positive cell population obtained when treated with a differentiation induction medium containing ALK5iII or a non-mutagenic ALK5 inhibitor (SB525334, SB431542, IN1130, EW-7197) are shown in Figure 2 Unlike ALK5iII, in the case of non-mutant ALK5 inhibitors (SB525334, SB431542, IN1130, EW-7197), the insulin-positive cell rate and NKX6.1-positive cell rate as well as the CHGA-positive cell rate and PDX1-positive cell rate were comparable to those of the control group (-), confirming that, unlike ALK5iII, the addition of non-mutant ALK5 inhibitors did not promote differentiation into the desired insulin-positive cells.

[0165] Since kinase inhibitors often interact with different targets, the kinase inhibition spectrum of ALK5iII was analyzed to confirm the off-target effects of ALK5iII. In this experiment, staurosporine derivatives bound to BODIPY-FL or Cy5-FL were used as fluorescent probes, and competitive binding assays were performed with 0.1μM and 1μM ALK5iII against approximately 350 different recombinant kinases. In this experiment, the pIC50 value was estimated based on the inhibitory activity values ​​at two concentrations of 0.1μM and 1μM, and the evaluation was performed according to the following method: more than 8.0 = out of the detection range (with strong inhibitory activity), 6.0-8.0 = with inhibitory activity, and less than 6.0 = no inhibitory activity was detected at concentrations as high as 1μM. The results are shown in Table 5 below. ALK5iII was confirmed to have inhibitory activity with an estimated pIC50 value greater than 6 against 11 kinases, including CDK8 and CDK19. In addition, 8.00±0.00 for ALK5 and ALK4 in the table indicates that the actual pIC50 values ​​estimated by extrapolation from the measured values ​​were greater than 8.

[0166]

Table 5

[0167] Next, the inhibitory activity of non-mutagenic ALK5 inhibitors (SB431542, SB525334, IN1130, and EW-7197) against the above 11 kinases was also evaluated. Interestingly, the results showed that the inhibitory activity against CDK8 and CDK19 (CDK8 / 19) was found to be specific to ALK5iII ( Figure 3 ). These results suggest that inhibition of CDK8 / 19 may help promote differentiation into insulin-positive cells.

[0168] Example 3: Combination of ALK5 inhibition and CDK8 / 19 inhibition mimics the effects of ALK5iII An insulin-positive cell population was prepared in the same manner as in the above-mentioned "Example 2" except that any one of the following (1)-(4) was used as ALK5iII or a non-mutagenic ALK5 inhibitor added to the culture medium in the method for preparing an insulin-positive cell population in the above-mentioned "Example 2". (1) ALK5iII 10μM, (2) Non-mutagenic ALK5 inhibitor SB431542 3μM, (3) CDK8 / 19 inhibitor Senexin B 0.3 μM, (4) Combination of SB431542 3 μM and Senexin B 0.3 μM. It should be noted that these inhibitors were used at concentrations that caused complete inhibition in time-resolved fluorescence resonance energy transfer (TR-FRET) cell-free dose-response assays.

[0169] The number of insulin-positive cells and NKX6.1-positive cells in the insulin-positive cell population obtained by the above method was counted using flow cytometry, and the respective cell rates in each cell population were calculated.

[0170] The results showed that when the combination of (4) SB431542 and Senexin B (SB / Sen) was used, the cell rates of insulin-positive cells and NKX6.1-positive cells were higher than those when (1) ALK5iII was used ( Figure 4 A), or the total cell yield of the two is similar ( Figure 4 B).

[0171] On the other hand, when only (2) ALK5 inhibitor SB431542 was used, the cell rate and total cell yield of insulin-positive cells and NKX6.1-positive cells were lower than when (1) ALK5iII was used ( Figure 4 A, B).

[0172] In addition, when only the CDK8 / 19 inhibitor SenexinB was used, the cell rates of insulin-positive cells and NKX6.1-positive cells were higher than those using (1) ALK5iII ( Figure 4 A), but the total cell yield was lower than that of cells using (1) ALK5iII ( Figure 4 B).

[0173] Single-cell RNA-seq (scRNA-seq) analysis was then performed to compare the cellular composition of the insulin-positive cell populations generated using each of the above inhibitors (1) to (4). The library for scRNA-seq analysis was prepared using the Chromium controller and preparation kit Chromium Next GEM Single Cell 3'kits v3.1 from 10x Genomics, and sequencing was performed using IlluminaHi using Illumina's Hi-seq platform. The obtained UMI counts were analyzed for data using CellRanger from 10XGenomics and the R package Seurat, and PCA and UMAP were used for dimensionality reduction and visualization. Cell clustering based on the dimensionality reduction results was performed based on the shared nearest neighbor method in Seurat.

[0174] As a result, among the insulin-positive cell populations generated using each of the above inhibitors (1) to (4), clusters 1 to 17 were identified. Based on the expression patterns of cell identification markers such as insulin and glucagon, and analysis based on the public database PanglaoDB (https: / / panglaodb.se / ) (O. Franzen, LMGan, JLM Bjorkegren, PanglaoDB: a web server for exploration of mouse and human single-cell RNAsequencing data. Database (Oxford) 2019 (2019).), clusters 1, 2, and 9 were identified to be close to β cells, α cells, and pancreatic acinar cells / duct cells, respectively. In addition, cells in clusters 3 and 6 had characteristics specific to enterochromaffin cells. Cluster 12 cells were considered to be relatively immature β cells because they expressed high levels of insulin and NKX6.1 but did not express β cell maturation markers such as MAFA and G6PC2, which distinguished them from the adjacent cluster 1 cells. In addition, some β cells may be incorporated into cluster 0 together with α, δ, and γ cells. Cluster 11 shows characteristics between hepatocytes and pancreatic α cells, while clusters 7 and 15 are most similar to neuron-like cells.

[0175] Comparing each cell cluster in the insulin-positive cell population produced using each of the above inhibitors (1) to (4), typical endocrine cells such as putative β cells, putative α cells and putative enterochromaffin cells (clusters 0, 1, 2, 3 and 6) were almost exclusively found in the insulin-positive cell population produced using the combination of (1) ALK5iII, (3) Senexin B, (4) SB431542 and Senexin B, whereas they were rarely found in the insulin-positive cell population produced using the ALK5 inhibitor SB431542. In addition, some other cell clusters (clusters 5, 9, 10, 12 and 13) were unique to the insulin-positive cell population produced using (2) the ALK5 inhibitor SB431542.

[0176] In addition, the ratio of each cluster (No. 1, 3, 6, and 12) in the insulin-positive cell population and NKX6.1-positive cell subpopulation prepared using each of the above inhibitors (1) to (4) is shown in Figure 5In the insulin-positive cell populations produced using each inhibitor of (1) ALK5iII and (4) a combination of SB431542 and Senexin B (SB / Sen), the proportions of each cluster were roughly the same, whereas the proportions of (2) ALK5 inhibitor SB431542 and (3) CDK8 / 19 inhibitor Senexin B inhibitor were different from their proportions in the insulin-positive cell populations produced by each inhibitor.

[0177] In addition, regarding gene expression in clusters 1 and 2 (putative β cells and putative α cells), the insulin-positive cell populations produced using (1) ALK5iII were compared with the insulin-positive cell populations produced using each of the other inhibitors, and it was found that in terms of the number of differentially expressed genes (DEGs) between the two samples, the lowest value was obtained in any cluster of the insulin-positive cell populations produced using each inhibitor (1) ALK5iII and (4) the combination of SB431542 and Senexin B ( Figure 6 ). These results indicate that the insulin-positive cell population produced using (1) ALK5iII and the insulin-positive cell population produced using (4) a combination of an ALK5 inhibitor and a CDK8 / 19 inhibitor have in vitro profiles close to each other.

[0178] Example 4: Evaluation of in vivo effectiveness of insulin-positive cell population obtained without using ALK5iII The effect on diabetes was evaluated in vivo using a combination of an ALK5 inhibitor and a CDK8 / 19 inhibitor (SB / Sen) without using an insulin-positive cell population produced by ALK5iII.

[0179] Low doses of streptozotocin (STZ, 50 mg / kg / day, 5 days, Sigma-Aldrich) were intraperitoneally administered to male NOD.CB17-Prkdcscid / J (NOD-scid) mice multiple times to induce type 1 diabetes. The insulin-positive cell population produced using (1) ALK5iII obtained in Example 3 and the insulin-positive cell population produced using (4) a combination of an ALK5 inhibitor and a CDK8 / 19 inhibitor (SB / Sen) were respectively embedded in a fibrin gel mixed with 10 mg / mL fibrinogen (Merck Millipore) and 50 IU / mL thrombin solution (Sigma-Aldrich) and transplanted subcutaneously (3×10 6The levels of glucose and human C-peptide in the plasma of each model mouse were measured every 2 or 4 weeks using ACCU-CHEK Aviva (Roche Diagnostics, Basel, Switzerland) and Ultrasensitive C-peptide ELISA (Mercodia AB, Uppsala, Sweden) according to the manufacturer's instructions.

[0180] Insulin-positive cell populations produced using (1) ALK5iII and (4) a combination of an ALK5 inhibitor and a CDK8 / 19 inhibitor (SB / Sen) transplanted into model mice showed comparable effects on lowering blood glucose and secreting human C-peptide ( Figure 7 A and B), all transplanted mice reached normal blood glucose levels within 8 weeks.

[0181] In addition, at 21 weeks after transplantation, when the model mice were subjected to an oral glucose tolerance test, the glucose tolerance response of all mice reached a peak at 15 minutes ( Figure 7 C and D).

[0182] In addition, the insulin-positive cell populations produced using (1) ALK5iII and the insulin-positive cell populations produced using (4) a combination of ALK5 inhibitor and CDK8 / 19 inhibitor (SB / Sen) transplanted into model mice were removed 6 months after transplantation and immunostained using antibodies against various markers of insulin-positive cells. It was confirmed that more glucagon-positive α cells appeared in each cell population than at the time of transplantation.

[0183] From the above results, it can be seen that by treating a cell population in the process of differentiating from a pancreatic precursor cell population into an insulin-positive cell population with a combination of a non-mutagenic ALK5 inhibitor and a CDK8 / 19 inhibitor instead of the mutagenic ALK5iII, an insulin-positive cell population having the same in vitro and in vivo properties as the insulin-positive cell population obtained by the previous method using ALK5iII can be produced.

Claims

1. A method for producing an insulin-positive cell population, The method comprises: Culturing and differentiating a pancreatic precursor cell population or a cell population at a subsequent differentiation stage in a medium containing a factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity, The culture medium is substantially free of 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine.

2. The method according to claim 1, wherein: The factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity comprises an ALK5 inhibitor and a CDK8 / 19 inhibitor.

3. The method according to claim 1 or 2, wherein: The CDK8 / 19 inhibitor is selected from diethyl (E)-(4-(3-(5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)acrylamide)benzyl)phosphonate, 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile, 4-(4-(2,3-dihydrobenzo[ One or more compounds or their salts thereof are selected from the group consisting of [b][1,4]dioxin-6-yl)-1H-pyrazol-3-yl)benzene-1,3-diol, 3-(2-(imidazo[1,2-b]pyridazin-6-ylthio)ethyl)-4-(naphthalen-1-ylsulfonyl)-3,4-dihydroquinoxalin-2(1H)-one, and (E)-3-(4-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinylmethyl)phenyl)acrylamide.

4. The method according to any one of claims 1 to 3, wherein: The ALK5 inhibitor is one or more compounds or their salts selected from the group consisting of 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, and 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline.

5. The method according to any one of claims 1 to 4, wherein: The CDK8 / 19 inhibitor is 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile or 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide or its salt, and the ALK5 inhibitor is 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide or its salt.

6. The method according to claim 1, wherein: The pancreatic precursor cell population or the cell population in a subsequent differentiation stage is produced by differentiating induced pluripotent stem cells.

7. A differentiation medium for a pancreatic precursor cell population or a cell population at a differentiation stage thereafter, the medium comprising factors having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity and being substantially free of 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine.

8. The culture medium according to claim 7, wherein The factor having ALK5 inhibitory activity and CDK8 / 19 inhibitory activity comprises an ALK5 inhibitor and a CDK8 / 19 inhibitor.

9. The culture medium according to claim 8, wherein The CDK8 / 19 inhibitor is selected from diethyl (E)-(4-(3-(5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)acrylamide)benzyl)phosphonate, 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide, 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile, 4-(4-(2,3-dihydrobenzo[ One or more compounds or their salts thereof are selected from the group consisting of [b][1,4]dioxin-6-yl)-1H-pyrazol-3-yl)benzene-1,3-diol, 3-(2-(imidazo[1,2-b]pyridazin-6-ylthio)ethyl)-4-(naphthalen-1-ylsulfonyl)-3,4-dihydroquinoxalin-2(1H)-one, and (E)-3-(4-(1-cyclopropyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinylmethyl)phenyl)acrylamide.

10. The culture medium according to claim 8, wherein the ALK5 inhibitor is one or more compounds selected from the group consisting of 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline, 3-[[5-(6-methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]benzamide, and 2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline, or a salt thereof.

11. The culture medium according to claim 8, wherein the CDK8 / 19 inhibitor is 4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile or 2-(4-(4-(isoquinolin-4-yl)phenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide or a salt thereof, and the ALK5 inhibitor is 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide or a salt thereof.

12. The culture medium according to claim 7, wherein The pancreatic precursor cell population or the cell population in a subsequent differentiation stage is produced by differentiating induced pluripotent stem cells.

Citation Information

Patent Citations

  • Method for producing induced pluripotent stem cell

    JP2008283972A

  • Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth

    JP2008307007A

  • Manufacturing method of electric wire with terminal

    JP2022071507A

  • Nuclear reprogramming factor and induced pluripotent stem cells

    US20090047263A1

  • CDKI pathway inhibitors and uses thereof

    US20120071477A1